ReviewCancers2021
Intrahepatic Cholangiocarcinoma: A Summative Review of Biomarkers and Targeted Therapies.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 39 citations in OpenAlex.
- Development and Validation of a Machine-Learning Model to Predict Early Recurrence of Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2023Trial
- Radiomics for Detection and Differentiation of Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis.Cancers · 2026Review
- Biliary Adenofibroma and the Threat of Malignant Transformation.International journal of surgical pathology · 2025Review
- Isocitrate dehydrogenase 1 gene mutations: a case review unveiling its biological impact on disease progression, prognosis and treatment in Chilean patients.BJR case reports · 2025Review
- HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma.Journal of experimental & clinical cancer research : CR · 2024Article
- Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?Life (Basel, Switzerland) · 2023Article
- IL-8 is a novel prometastatic chemokine in intrahepatic cholangiocarcinoma that induces CXCR2-PI3K/AKT signaling upon CD97 activation.Scientific reports · 2023Article
- ASO Author Reflections: Use of Machine Learning to Predict Early Recurrence After Resection of Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2023Article
- Impact of Staging Concordance and Downstaging After Neoadjuvant Therapy on Survival Following Resection of Intrahepatic Cholangiocarcinoma: A Bayesian Analysis.Annals of surgical oncology · 2023Article
- ASO Author Reflections: Accuracy of Preoperative Staging and Downstaging After Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2023Article
- Surgical Aspects of Intrahepatic Cholangiocarcinoma.Cancers · 2022Review
- Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma.Scientific reports · 2022Article
- Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives.International journal of molecular sciences · 2022Review
- Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma.Frontiers in medicine · 2022Review
- Ferroptosis in Intrahepatic Cholangiocarcinoma:Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although rare, intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy and the incidence of ICC has increased 14% per year in recent decades. Treatment of ICC remains difficult as most people present with advanced disease not amenable to curative-intent surgical resection. Even among patients with operable disease, margin-negative surgical resection can be difficult to achieve and the incidence of recurrence remains high. As such, there has been considerable interest in systemic chemotherapy and targeted therapy for ICC. Over the last decade, the understanding of the molecular and genetic foundations of ICC has reshaped treatment approaches and strategies. Next-generation sequencing has revealed that most ICC tumors have at least one targetable mutation. These advancements have led to multiple clinical trials to examine the safety and efficacy of novel therapeutics that target tumor-specific molecular and genetic aberrations. While these advancements have demonstrated survival benefit in early phase clinical trials, continued investigation in randomized larger-scale trials is needed to further define the potential clinical impact of such therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.